Jove
Visualize
Contact Us

Related Experiment Videos

Some considerations regarding active immunization with HBsAg.

A M Prince, N Hashimoto, A R Neurath

    Developments in Biological Standardization
    |January 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Methodology Used in DNA-Based Prophylactic and Therapeutic Immunization Against Hepatitis B Virus in Chimpanzees.

    Methods in molecular medicine·2011
    Same author

    Development of the International Consortium for Blood Safety (ICBS) HCV panels.

    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit·2008
    Same author

    Schistosoma infection inhibits cellular immune responses to core HCV peptides.

    Parasite immunology·2005
    Same author

    Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation.

    Antimicrobial agents and chemotherapy·2004
    Same author

    Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections.

    Journal of viral hepatitis·2004
    Same author

    Perspectives on prophylactic and therapeutic immunization against hepatitis B and C viruses.

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2002
    Same journal

    International challenges and public policy issues.

    Developments in biological standardization·2000
    Same journal

    Regulation of biologicals in China.

    Developments in biological standardization·2000
    Same journal

    ICH activities on biotech topics.

    Developments in biological standardization·2000
    Same journal

    Regulation of biologicals in the European Union.

    Developments in biological standardization·2000
    Same journal

    Standardisation and licensing of combination vaccines based on DTP.

    Developments in biological standardization·2000
    Same journal

    Control of foot-and-mouth disease by vaccination.

    Developments in biological standardization·2000
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Injecting heated hepatitis B surface antigen (HBsAg) shows promise for protection against hepatitis B virus (HBV). Further research is needed to optimize inactivation and immunization for human trials.

    Area of Science:

    • Hepatology
    • Immunology
    • Virology

    Background:

    • Previous studies demonstrated that heated serum containing hepatitis B surface antigen (HBsAg) offered partial protection against hepatitis B virus (HBV) challenge.
    • Increased quantities of purified HBsAg may enhance protective immunity.
    • Investigating the inactivation kinetics of HBsAg antigenicity and immunogenicity is crucial for vaccine development.

    Purpose of the Study:

    • To investigate the inactivation kinetics of HBsAg antigenicity and immunogenicity by heat.
    • To assess the safety and efficacy of HBsAg inactivation procedures for potential human trials.
    • To establish optimal dose and immunization schedules for HBV vaccination.

    Main Methods:

    • Preliminary studies were conducted in mice to examine heat inactivation rates of HBsAg.

    Related Experiment Videos

  • Chimpanzees were utilized to determine the adequacy of inactivation procedures and immunization strategies.
  • A dedicated laboratory was established in West Africa for chimpanzee trials, using isolated, trapped animals to mitigate risks.

    • Main Results:

    • Heat inactivation rates for HBsAg antigenicity and immunogenicity were found to be parallel in mice.
    • Newly imported chimpanzees pose a risk due to potential pre-existing hepatitis B infections, necessitating quarantine.
    • Even after vaccination and prior exposure, chimpanzees receiving massive infective plasma developed severe hepatitis, indicating limitations in achieving absolute immunity.

    Conclusions:

    • Heat inactivation appears to be a parallel process for HBsAg antigenicity and immunogenicity.
    • Rigorous quarantine and isolation protocols for chimpanzees are essential to prevent false positives in inactivation trials.
    • Current HBV immunization strategies may not confer absolute immunity, highlighting the need for ongoing research and development.